APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Opioid Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchOpioid Antagonist Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Antagonist Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Opioid Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Antagonist Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Antagonist Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Opioid Antagonist market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Opioid Antagonist include Titan Pharmaceuticals, AstraZeneca, Shionogi, Orexo, Opiant Pharmaceuticals, Indivior, Hikma Pharmaceuticals, Collegium Pharmaceutical and Camurus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Opioid Antagonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioid Antagonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioid Antagonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioid Antagonist market size, projected growth trends, production technologies, key applications, and end-use industries.

Opioid Antagonist Segment by Company

Titan Pharmaceuticals

AstraZeneca

Shionogi

Orexo

Opiant Pharmaceuticals

Indivior

Hikma Pharmaceuticals

Collegium Pharmaceutical

Camurus

BioDelivery Sciences International

Alkermes

Acura Pharmaceuticals

Opioid Antagonist Segment by Type

Oral

Parenteral

Opioid Antagonist Segment by Application

Hospitals

Clinics

Others

Opioid Antagonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioid Antagonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Opioid Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Opioid Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Opioid Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Opioid Antagonist Industry Trends Table 2. Opioid Antagonist Industry Drivers Table 3. Opioid Antagonist Industry Opportunities and Challenges Table 4. Opioid Antagonist Industry Restraints Table 5. Global Opioid Antagonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Opioid Antagonist Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Opioid Antagonist Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Opioid Antagonist Sales Market Share by Manufacturers Table 9. Global Opioid Antagonist Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Opioid Antagonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Opioid Antagonist Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Opioid Antagonist Manufacturers, Product Type & Application Table 13. Global Opioid Antagonist Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Opioid Antagonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oral Table 17. Major Manufacturers of Parenteral Table 18. Global Opioid Antagonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Opioid Antagonist Sales by Type (2021-2026) & (K Units) Table 20. Global Opioid Antagonist Sales by Type (2027-2032) & (K Units) Table 21. Global Opioid Antagonist Sales Market Share by Type (2021-2026) Table 22. Global Opioid Antagonist Sales Market Share by Type (2027-2032) Table 23. Global Opioid Antagonist Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Opioid Antagonist Revenue by Type (2021-2026) & (K Units) Table 25. Global Opioid Antagonist Revenue by Type (2027-2032) & (K Units) Table 26. Global Opioid Antagonist Revenue Market Share by Type (2021-2026) Table 27. Global Opioid Antagonist Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospitals Table 29. Major Manufacturers of Clinics Table 30. Major Manufacturers of Others Table 31. Global Opioid Antagonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Opioid Antagonist Sales by Application (2021-2026) & (K Units) Table 33. Global Opioid Antagonist Sales by Application (2027-2032) & (K Units) Table 34. Global Opioid Antagonist Sales Market Share by Application (2021-2026) Table 35. Global Opioid Antagonist Sales Market Share by Application (2027-2032) Table 36. Global Opioid Antagonist Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Opioid Antagonist Revenue by Application (2021-2026) & (K Units) Table 38. Global Opioid Antagonist Revenue by Application (2027-2032) & (K Units) Table 39. Global Opioid Antagonist Revenue Market Share by Application (2021-2026) Table 40. Global Opioid Antagonist Revenue Market Share by Application (2027-2032) Table 41. Global Opioid Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Opioid Antagonist Sales by Region (2021-2026) & (K Units) Table 43. Global Opioid Antagonist Sales Market Share by Region (2021-2026) Table 44. Global Opioid Antagonist Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Opioid Antagonist Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Opioid Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 48. North America Opioid Antagonist Sales by Country (2027-2032) & (K Units) Table 49. Europe Opioid Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 51. Europe Opioid Antagonist Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Opioid Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Opioid Antagonist Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Opioid Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Opioid Antagonist Sales by Country (2027-2032) & (K Units) Table 58. Global Opioid Antagonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Opioid Antagonist Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Opioid Antagonist Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Opioid Antagonist Revenue Market Share by Region (2021-2026) Table 62. Global Opioid Antagonist Revenue Market Share by Region (2027-2032) Table 63. Titan Pharmaceuticals Company Information Table 64. Titan Pharmaceuticals Business Overview Table 65. Titan Pharmaceuticals Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Titan Pharmaceuticals Opioid Antagonist Product Portfolio Table 67. Titan Pharmaceuticals Recent Development Table 68. AstraZeneca Company Information Table 69. AstraZeneca Business Overview Table 70. AstraZeneca Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. AstraZeneca Opioid Antagonist Product Portfolio Table 72. AstraZeneca Recent Development Table 73. Shionogi Company Information Table 74. Shionogi Business Overview Table 75. Shionogi Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Shionogi Opioid Antagonist Product Portfolio Table 77. Shionogi Recent Development Table 78. Orexo Company Information Table 79. Orexo Business Overview Table 80. Orexo Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Orexo Opioid Antagonist Product Portfolio Table 82. Orexo Recent Development Table 83. Opiant Pharmaceuticals Company Information Table 84. Opiant Pharmaceuticals Business Overview Table 85. Opiant Pharmaceuticals Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Opiant Pharmaceuticals Opioid Antagonist Product Portfolio Table 87. Opiant Pharmaceuticals Recent Development Table 88. Indivior Company Information Table 89. Indivior Business Overview Table 90. Indivior Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Indivior Opioid Antagonist Product Portfolio Table 92. Indivior Recent Development Table 93. Hikma Pharmaceuticals Company Information Table 94. Hikma Pharmaceuticals Business Overview Table 95. Hikma Pharmaceuticals Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Hikma Pharmaceuticals Opioid Antagonist Product Portfolio Table 97. Hikma Pharmaceuticals Recent Development Table 98. Collegium Pharmaceutical Company Information Table 99. Collegium Pharmaceutical Business Overview Table 100. Collegium Pharmaceutical Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Collegium Pharmaceutical Opioid Antagonist Product Portfolio Table 102. Collegium Pharmaceutical Recent Development Table 103. Camurus Company Information Table 104. Camurus Business Overview Table 105. Camurus Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Camurus Opioid Antagonist Product Portfolio Table 107. Camurus Recent Development Table 108. BioDelivery Sciences International Company Information Table 109. BioDelivery Sciences International Business Overview Table 110. BioDelivery Sciences International Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. BioDelivery Sciences International Opioid Antagonist Product Portfolio Table 112. BioDelivery Sciences International Recent Development Table 113. Alkermes Company Information Table 114. Alkermes Business Overview Table 115. Alkermes Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Alkermes Opioid Antagonist Product Portfolio Table 117. Alkermes Recent Development Table 118. Acura Pharmaceuticals Company Information Table 119. Acura Pharmaceuticals Business Overview Table 120. Acura Pharmaceuticals Opioid Antagonist Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Acura Pharmaceuticals Opioid Antagonist Product Portfolio Table 122. Acura Pharmaceuticals Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. Opioid Antagonist Distributors List Table 126. Opioid Antagonist Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Opioid Antagonist Product Image Figure 2. Global Opioid Antagonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Antagonist Market Size (2021-2032) & (US$ Million) Figure 4. Global Opioid Antagonist Sales (2021-2032) & (K Units) Figure 5. Global Opioid Antagonist Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Opioid Antagonist Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oral Image Figure 9. Parenteral Image Figure 10. Global Opioid Antagonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Opioid Antagonist Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Opioid Antagonist Sales Market Share by Type (2021-2032) Figure 13. Global Opioid Antagonist Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Opioid Antagonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Opioid Antagonist Revenue Market Share by Type (2021-2032) Figure 16. Hospitals Image Figure 17. Clinics Image Figure 18. Others Image Figure 19. Global Opioid Antagonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Opioid Antagonist Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Opioid Antagonist Sales Market Share by Application (2021-2032) Figure 22. Global Opioid Antagonist Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Opioid Antagonist Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Opioid Antagonist Revenue Market Share by Application (2021-2032) Figure 25. North America Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Opioid Antagonist Sales Market Share by Country (2021-2032) Figure 27. U.S. Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Opioid Antagonist Sales Market Share by Country (2021-2032) Figure 32. Germany Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Opioid Antagonist Sales Market Share by Country (2021-2032) Figure 39. China Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Opioid Antagonist Sales Market Share by Country (2021-2032) Figure 47. Brazil Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Opioid Antagonist Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Opioid Antagonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Opioid Antagonist Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Opioid Antagonist Revenue (2021-2032) & (US$ Million) Figure 58. North America Opioid Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Opioid Antagonist Revenue (2021-2032) & (US$ Million) Figure 60. Europe Opioid Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Opioid Antagonist Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Opioid Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Opioid Antagonist Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Opioid Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Opioid Antagonist Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Opioid Antagonist Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Parenteral
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Titan Pharmaceuticals
  • AstraZeneca
  • Shionogi
  • Orexo
  • Opiant Pharmaceuticals
  • Indivior
  • Hikma Pharmaceuticals
  • Collegium Pharmaceutical
  • Camurus
  • BioDelivery Sciences International
  • Alkermes
  • Acura Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Opioid Antagonist Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Opioid Antagonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Opioid Antagonist Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Opioid Antagonist Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Opioid Antagonist Market Dynamics
  1. 2.1 Opioid Antagonist Industry Trends
  2. 2.2 Opioid Antagonist Industry Drivers
  3. 2.3 Opioid Antagonist Industry Opportunities and Challenges
  4. 2.4 Opioid Antagonist Industry Restraints
3 Opioid Antagonist Market by Manufacturers
  1. 3.1 Global Opioid Antagonist Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Opioid Antagonist Sales by Manufacturers (2021-2026)
  3. 3.3 Global Opioid Antagonist Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Opioid Antagonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Opioid Antagonist Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Opioid Antagonist Manufacturers, Product Type & Application
  7. 3.7 Global Opioid Antagonist Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Opioid Antagonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Opioid Antagonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Opioid Antagonist Tier 1, Tier 2, and Tier 3
4 Opioid Antagonist Market by Type
  1. 4.1 Opioid Antagonist Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Parenteral
  4. 4.2 Global Opioid Antagonist Sales by Type
  5. 4.2.1 Global Opioid Antagonist Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Opioid Antagonist Sales by Type (2021-2032)
  7. 4.2.3 Global Opioid Antagonist Sales Market Share by Type (2021-2032)
  8. 4.3 Global Opioid Antagonist Revenue by Type
  9. 4.3.1 Global Opioid Antagonist Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Opioid Antagonist Revenue by Type (2021-2032)
  11. 4.3.3 Global Opioid Antagonist Revenue Market Share by Type (2021-2032)
5 Opioid Antagonist Market by Application
  1. 5.1 Opioid Antagonist Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Opioid Antagonist Sales by Application
  6. 5.2.1 Global Opioid Antagonist Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid Antagonist Sales by Application (2021-2032)
  8. 5.2.3 Global Opioid Antagonist Sales Market Share by Application (2021-2032)
  9. 5.3 Global Opioid Antagonist Revenue by Application
  10. 5.3.1 Global Opioid Antagonist Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Opioid Antagonist Revenue by Application (2021-2032)
  12. 5.3.3 Global Opioid Antagonist Revenue Market Share by Application (2021-2032)
6 Global Opioid Antagonist Sales by Region
  1. 6.1 Global Opioid Antagonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioid Antagonist Sales by Region (2021-2032)
  3. 6.2.1 Global Opioid Antagonist Sales by Region (2021-2026)
  4. 6.2.2 Global Opioid Antagonist Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Opioid Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Opioid Antagonist Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Opioid Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Opioid Antagonist Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Opioid Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Opioid Antagonist Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Opioid Antagonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Opioid Antagonist Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Opioid Antagonist Revenue by Region
  1. 7.1 Global Opioid Antagonist Revenue by Region
  2. 7.1.1 Global Opioid Antagonist Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Opioid Antagonist Revenue by Region (2021-2026)
  4. 7.1.3 Global Opioid Antagonist Revenue by Region (2027-2032)
  5. 7.1.4 Global Opioid Antagonist Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Opioid Antagonist Revenue (2021-2032)
  8. 7.2.2 North America Opioid Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Opioid Antagonist Revenue (2021-2032)
  11. 7.3.2 Europe Opioid Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Opioid Antagonist Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Opioid Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Opioid Antagonist Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Opioid Antagonist Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Titan Pharmaceuticals
  2. 8.1.1 Titan Pharmaceuticals Company Information
  3. 8.1.2 Titan Pharmaceuticals Business Overview
  4. 8.1.3 Titan Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Titan Pharmaceuticals Opioid Antagonist Product Portfolio
  6. 8.1.5 Titan Pharmaceuticals Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca Opioid Antagonist Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Shionogi
  14. 8.3.1 Shionogi Company Information
  15. 8.3.2 Shionogi Business Overview
  16. 8.3.3 Shionogi Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shionogi Opioid Antagonist Product Portfolio
  18. 8.3.5 Shionogi Recent Developments
  19. 8.4 Orexo
  20. 8.4.1 Orexo Company Information
  21. 8.4.2 Orexo Business Overview
  22. 8.4.3 Orexo Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Orexo Opioid Antagonist Product Portfolio
  24. 8.4.5 Orexo Recent Developments
  25. 8.5 Opiant Pharmaceuticals
  26. 8.5.1 Opiant Pharmaceuticals Company Information
  27. 8.5.2 Opiant Pharmaceuticals Business Overview
  28. 8.5.3 Opiant Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Opiant Pharmaceuticals Opioid Antagonist Product Portfolio
  30. 8.5.5 Opiant Pharmaceuticals Recent Developments
  31. 8.6 Indivior
  32. 8.6.1 Indivior Company Information
  33. 8.6.2 Indivior Business Overview
  34. 8.6.3 Indivior Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Indivior Opioid Antagonist Product Portfolio
  36. 8.6.5 Indivior Recent Developments
  37. 8.7 Hikma Pharmaceuticals
  38. 8.7.1 Hikma Pharmaceuticals Company Information
  39. 8.7.2 Hikma Pharmaceuticals Business Overview
  40. 8.7.3 Hikma Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hikma Pharmaceuticals Opioid Antagonist Product Portfolio
  42. 8.7.5 Hikma Pharmaceuticals Recent Developments
  43. 8.8 Collegium Pharmaceutical
  44. 8.8.1 Collegium Pharmaceutical Company Information
  45. 8.8.2 Collegium Pharmaceutical Business Overview
  46. 8.8.3 Collegium Pharmaceutical Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Collegium Pharmaceutical Opioid Antagonist Product Portfolio
  48. 8.8.5 Collegium Pharmaceutical Recent Developments
  49. 8.9 Camurus
  50. 8.9.1 Camurus Company Information
  51. 8.9.2 Camurus Business Overview
  52. 8.9.3 Camurus Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Camurus Opioid Antagonist Product Portfolio
  54. 8.9.5 Camurus Recent Developments
  55. 8.10 BioDelivery Sciences International
  56. 8.10.1 BioDelivery Sciences International Company Information
  57. 8.10.2 BioDelivery Sciences International Business Overview
  58. 8.10.3 BioDelivery Sciences International Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 BioDelivery Sciences International Opioid Antagonist Product Portfolio
  60. 8.10.5 BioDelivery Sciences International Recent Developments
  61. 8.11 Alkermes
  62. 8.11.1 Alkermes Company Information
  63. 8.11.2 Alkermes Business Overview
  64. 8.11.3 Alkermes Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Alkermes Opioid Antagonist Product Portfolio
  66. 8.11.5 Alkermes Recent Developments
  67. 8.12 Acura Pharmaceuticals
  68. 8.12.1 Acura Pharmaceuticals Company Information
  69. 8.12.2 Acura Pharmaceuticals Business Overview
  70. 8.12.3 Acura Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Acura Pharmaceuticals Opioid Antagonist Product Portfolio
  72. 8.12.5 Acura Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Opioid Antagonist Value Chain Analysis
  2. 9.1.1 Opioid Antagonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Opioid Antagonist Production Mode & Process
  6. 9.2 Opioid Antagonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Opioid Antagonist Distributors
  9. 9.2.3 Opioid Antagonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst